News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,314 Results
Type
Article (13871)
Company Profile (294)
Press Release (246149)
Section
Business (79328)
Career Advice (150)
Deals (13180)
Drug Delivery (32)
Drug Development (50295)
Employer Resources (31)
FDA (5670)
Job Trends (5113)
News (144078)
Policy (10016)
Tag
Academia (901)
Alliances (21471)
Alzheimer's disease (736)
Approvals (5644)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4497)
Biotechnology (242)
Breast cancer (66)
Cancer (694)
Cardiovascular disease (62)
Career advice (131)
CAR-T (56)
Cell therapy (176)
Clinical research (39817)
Collaboration (238)
Compensation (97)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (792)
Diabetes (73)
Diagnostics (1200)
Earnings (28976)
Events (46844)
Executive appointments (193)
FDA (5962)
Funding (247)
Gene editing (55)
Gene therapy (147)
GLP-1 (300)
Government (1063)
Healthcare (6533)
Infectious disease (1037)
Inflammatory bowel disease (94)
IPO (7179)
Job creations (859)
Job search strategy (126)
Layoffs (184)
Legal (1373)
Lung cancer (111)
Manufacturing (74)
Medical device (2555)
Medtech (2556)
Mergers & acquisitions (6102)
Metabolic disorders (225)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (843)
Northern California (947)
Obesity (124)
Opinion (91)
Parkinson's disease (61)
Patents (52)
People (24981)
Pharmaceutical (49)
Phase I (14005)
Phase II (18523)
Phase III (11739)
Pipeline (321)
Postmarket research (847)
Preclinical (5929)
Radiopharmaceuticals (205)
Rare diseases (168)
Real estate (1409)
Regulatory (8204)
Research institute (930)
Southern California (866)
Startups (1965)
United States (7620)
Vaccines (159)
Weight loss (76)
Date
Today (66)
Last 7 days (487)
Last 30 days (2298)
Last 365 days (20705)
2024 (19010)
2023 (22414)
2022 (26825)
2021 (27808)
2020 (23361)
2019 (16230)
2018 (11741)
2017 (13747)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7487)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (146)
Asia (16834)
Australia (2837)
California (2150)
Canada (713)
China (163)
Colorado (81)
Connecticut (85)
Europe (36246)
Florida (229)
Georgia (62)
Illinois (126)
Indiana (54)
Kansas (55)
Maryland (300)
Massachusetts (1706)
Michigan (48)
Minnesota (93)
New Jersey (546)
New York (611)
North Carolina (399)
Northern California (947)
Ohio (79)
Pennsylvania (429)
South America (207)
Southern California (866)
Texas (228)
Washington State (219)
260,314 Results for "adagio therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Adagio Medical Reports Third Quarter 2024 Results
November 14, 2024
·
6 min read
Biotech Beach
Adagio Medical Announces First European Commercial Procedures and Commencement of U.S. FDA Pivotal IDE for Ventricular Tachycardia Cryoablation System
Adagio Medical, Inc. (“Adagio Medical”, “Adagio” or the “Company”) today announced the completion of the first commercial procedures using its recently CE-Marked VT Cryoablation System and the U.S. Food and Drug Administration (“FDA”) approval of the FULCRUM-VT Pivotal IDE study of the VT Cryoablation System.
May 16, 2024
·
12 min read
Press Releases
Adagio Medical Announces Participation in the 19th Annual International Symposium on Ventricular Arrhythmias
October 7, 2024
·
1 min read
Biotech Beach
Adagio Medical Announces Initiation and First Procedure in FULCRUM-VT Trial, Starting The Process For Bringing Ultra-Low Temperature Cryoablation for Ventricular Arrhythmias to US Market
Adagio Medical, Inc. announced the first ultra-low temperature cryoablation (ULTC) procedure performed using the Adagio vCLAS™ catheter system in the United States as part of the FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation for Recurring Monomorphic Ventricular Tachycardia) clinical trial, NCT # NCT05675865.
September 13, 2023
·
4 min read
Policy
Adagio Medical Announces Completion of Enrollment in Cryocure-VT Trial, Maps the Pathway to CE-Mark of vCLAS™ VT Ablation Catheter
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation and ventricular tachycardia, announced the completion of enrollment in its Cryocure-VT trial of ultra-low temperature cryoablation for the treatment of monomorphic ventricular tachycardias.
May 3, 2023
·
3 min read
Business
Movers & Shakers: Adagio, Harpoon, Aravive, Nitrase and More
Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.
July 7, 2022
·
4 min read
·
Alex Keown
Biotech Beach
Adagio Medical Announces Initiation and First Patient Enrollment in PARALELL Trial To Investigate Safety and Performance of CryoPulse™ Catheter System for Pulsed Field Ablation and Pulsed Field Cryoablation of Persistent Atrial Fibrillation
Adagio Medical, Inc. announced its first pulsed field cryoablation (PFCA) procedure performed using the Adagio CryoPulse™ catheter system as part of the PARALELL (Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibriLlation) clinical trial, NCT #05408754.
October 24, 2022
·
3 min read
Drug Development
Gerngross Hits Exit Button as Adagio Prepares for Potential EUA Bid
Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.
February 22, 2022
·
2 min read
·
Alex Keown
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
Adagio Names Temp CEO, Outlines Plans for COVID-19 Antibody
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
February 24, 2022
·
2 min read
·
Vanessa Doctor, RN
1 of 26,032
Next
